A new scoping review examines the impact of respiratory bacteria on the severity of respiratory syncytial virus (RSV) ...

The FDA has started a review of MSD's respiratory syncytial virus (RSV) antibody clesrovimab, with a verdict due in the middle of next year. If approved by the 10th June action date, clesrovimab ...

By drawing attention to the broader impact among varied populations, we want to see more done to reveal the hidden burden that is RSV. Regulators have started reviews of GSK's depemokimab ...

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children under two years old, resulting in significant morbidity and a heavy economic burden on healthcare ...

Flu levels have surged to their highest levels since the 2009 swine flu pandemic, with influenza-related emergency department visits remaining very high across the U.S. The flu continues to drive the ...

The study, published Jan. 20 in The Lancet Infectious Diseases, found the vaccine to be 78% effective against RSV infection, 79% effective against emergency department and urgent care visits and 80% ...

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

Emergency visits related to the flu and RSV remain high and very high in the ... The Florida Department of Health’s Jan. 4 flu review showed that flu positivity rate and emergency room visits ...

Concerns about GBS arose during the review of safety data from clinical ... of lower respiratory tract disease (LRTD) associated with RSV in adults aged 60 years or more, and has since been ...

Community wastewater surveillance as of Jan. 8 shows moderate concentrations of the virus that causes COVID-19 and high concentrations of RSV and influenza A in Clark County, the release said.